Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the CD-19 Antibody Market Grown from 2024 to 2025?
In recent times, the CD-19 antibody market has seen significant growth and this trend is expected to continue. Anticipated to rise from $1.75 billion in 2024 to $1.91 billion in 2025, the market will experience a compound annual growth rate (CAGR) of 9.3%. The substantial growth in the historical period is linked to several factors such as the increased incidence of B-cell malignancies, advancements in immunotherapy, a surge in funding for oncology research, emergence of CAR-T cell therapies, growing awareness about healthcare, and the broadening of personalized medicine.
What Growth Rate Is Anticipated for the CD-19 Antibody Market in the Coming Years?
Anticipations for the CD-19 antibody market forecast considerable expansion in the years to come. This sector is projected to increase to $2.70 billion in 2029 with a compound annual growth rate (CAGR) of 9.0%. Several variables can be credited for the expected growth, such as the burgeoning demand for specialized cancer treatments, escalating acceptance of smart cell therapies, the increasing occurrence of hematologic malignancies. Other factors include better healthcare accessibility in emerging markets, and the evolution of next-generation immunotherapies and enhancements in biomanufacturing technologies. Noteworthy trends for the forecast period encompass advancements in antibody-drug conjugation, the emergence of bispecific antibodies, the application of AI in antibody blueprint, advancements in cell therapy platforms, inclinations towards single-use bioreactors, the rise of nanobody-based treatments, and the integration of automation in biologics production.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21130&type=smp
Who Are the Leading Companies in the CD-19 Antibody Market?
Major companies operating in the CD-19 antibody market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc, Novartis AG, Thermo Fisher Scientific Inc., Amgen Inc., Bio-Rad Laboratories Inc., Miltenyi Biotec GmbH, Abcam Plc, Kite Pharma Inc., BioLegend Inc., Xencor Inc., Juno Therapeutics Inc., BD Biosciences, Zenas BioPharma Inc., Cell Signaling Technology Inc., Santa Cruz Biotechnology Inc., Novus Biologicals LLC, Tonbo Biosciences Inc., Bio X Cell Inc.
What Are the Key Drivers of the CD-19 Antibody Market?
The escalating incidence of B-cell malignancies is set to drive the expansion of the CD-19 antibody market in the future. B-cell malignancies are a categorization of cancers that emerge from atypical B lymphocytes, encompassing conditions like B-cell lymphomas and leukemias, these affect the immune system and can lead to rampant cell growth. The escalating incidence of B-cell malignancies is credited to a range of reasons including an aging demographic, genetic causes, environmental contact, lifestyle, enhanced detection, and adjustments within the immune system. CD19 antibody assists in treating B-cell malignancies by zeroing in on the CD19 protein on the exterior of malignant B cells, triggering their dissolution while preserving healthy cells and amplifying the body’s immune response. For example, in January 2024, the American Cancer Society, a non-profit organization based in the US, declared that approximately 80,620 individuals were presumed to be diagnosed with non-Hodgkin lymphoma in the US, alongside 20,240 individuals, consisting of 44,590 males and 36,030 females, anticipated to pass away as a result of non-Hodgkin lymphoma. Hence, the escalating incidence of B-cell malignancies is steering the growth of the CD-19 antibody market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21130&type=smp
What Are the Key Market Segments in the CD-19 Antibody Industry?
The CD-19 antibody market covered in this report is segmented –
1) By Disease Type: B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Other Disease Types
2) By Type: Polyclonal, Monoclonal
3) By Route Of Administration: Intravenous, Subcutaneous
4) By Application: Enzyme Linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry Frozen, Immunohistochemistry Paraffin, Other Applications
Subsegments:
1) By B-Cell Non-Hodgkin Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Mantle Cell Lymphoma
2) By Chronic Lymphocytic Leukemia: Relapsed Or Refractory CLL, Treatment-Naïve CLL
3) By Acute Lymphoblastic Leukemia: B-Cell Precursor ALL, Philadelphia Chromosome-Positive ALL
4) By Other Disease Types: Hairy Cell Leukemia, Waldenström’s Macroglobulinemia, Marginal Zone Lymphoma
What Are the Latest Trends in the CD-19 Antibody Market?
In the CD-19 antibody market, key players are devoting their efforts to technological advancements, including genetically engineered autologous T-cell immunotherapy, in order to improve the effectiveness of cancer treatments, specifically for blood cancers. This therapy involves modifying a patient’s own T cells genetically to recognize and destroy cancer cells, which are then reinserted into the patient’s body to boost the immune response against the disease. For example, Autolus Therapeutics plc, a US biotech firm, received U.S. FDA approval in November 2024 for AUCATZYL (obecabtagene autoleucel). This is intended for treating adults suffering from relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The goal of this approach is to lessen excessive T-cell activation, thus reducing toxicity and increasing the durability of the therapeutic cells. The therapy is given as two separate doses on the first and tenth day, with the doses tailored based on a bone marrow evaluation prior to treatment.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/cd-19-antibody-global-market-report
What Are the Key Regional Markets in the CD-19 Antibody Industry?
North America was the largest region in the CD-19 antibody market in 2024. The regions covered in the CD-19 antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21130
This Report Delivers Insight On:
1. How big is the cd-19 antibody market, and how is it changing globally?
2. Who are the major companies in the cd-19 antibody market, and how are they performing?
3. What are the key opportunities and risks in the cd-19 antibody market right now?
4. Which products or customer segments are growing the most in the cd-19 antibody market?
5. What factors are helping or slowing down the growth of the cd-19 antibody market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model